Introduction
============

Colorectal cancer (CRC) is one of the most common malignancies and is becoming the fifth leading cause of cancer death in China.[@b1-ott-11-4609] It is reported that the incidence rate and CRC-related mortality are increasing rapidly worldwide.[@b2-ott-11-4609],[@b3-ott-11-4609] These may be attributed to certain lifestyles and environmental factors, including physically inactive, overweight, smoking, and drinking. Recently, Katsidzira et al[@b4-ott-11-4609] reported that diabetes mellitus, previous schistosomiasis, approximation to a western lifestyle, and family history were the predominant associations with CRC. Besides these unhealthy lifestyle and environmental risk factors, genetic factors may also affect the development of CRC. A previous study demonstrated that genetic risk factors may contribute to \~35% etiology of CRC cases.[@b5-ott-11-4609] Up to now, the inherited factor of CRC remains controversial. Recently, a number of investigations have been devoted to exploring the potential molecular mechanism of CRC carcinogenesis, and inherited factors have been considered to play a vital role in the occurrence and development of CRC.[@b6-ott-11-4609],[@b7-ott-11-4609] Investigations of these conceivable inherited factors may enrich our view on the etiology of CRC.

The *cytotoxic T-lymphocyte antigen-4* (*CTLA-4*) gene, also named as a cluster of differentiation 152 (*CD152*), is one of the costimulatory molecule genes involved in immune response. CTLA-4 is transiently expressed on some activated T cells.[@b8-ott-11-4609] The expression of CTLA-4 inhibits cytokine production of T cells and then provides a negative signal to T cells.[@b9-ott-11-4609],[@b10-ott-11-4609] The structure of CTLA-4 shares some homologies with CD28 and binds to B7.1 and B7.2 ligands competitively. However, CTLA-4 has a higher binding affinity with B7 molecules compared with CD28. Through interaction of CTLA-4 with B7 molecules, T-cell proliferation, activation, and cytokine production can be inhibited.[@b11-ott-11-4609]--[@b13-ott-11-4609] The *CTLA-4* gene is located in chromosome 2q33, which belongs to several immune regulatory gene regions. Since CTLA-4 acts as a vital regulatory factor for some immune responses, any genetic variation in *CTLA-4* gene may influence normal immune function and then alter the risk of cancer. Hence, exploring the impact of these genetic variations in *CTLA-4* gene could determine their relationship with cancer susceptibility. CTLA-4 is polymorphic and contains more than 100 single-nucleotide polymorphisms (SNPs). Among them, some SNPs (eg, rs3087243 G\>A, rs16840252 C\>T, rs4553808 T\>C, rs5742909 C\>T, rs733618 T\>C, and rs231775 G\>A polymorphisms) in *CTLA-4* gene were extensively studied and were reported to be correlated with risk of human malignancy.[@b14-ott-11-4609],[@b15-ott-11-4609] Some case--control studies explored the relationship between *CTLA-4* polymorphisms and CRC;[@b16-ott-11-4609],[@b17-ott-11-4609] however, the sample sizes were limited and the results remained conflicting.

The evasion of immune surveillance and the production of immunosuppressive cytokines are two of the most common immune defects identified to be correlated with CRC. *CTLA-4* is a candidate gene which has been implicated in immune response.[@b18-ott-11-4609] Moreover, due to the emerging role of CTLA-4 as an immune checkpoint molecule, anti-CTLA-4 antibody has been tested recently in the treatment of CRC patients.[@b19-ott-11-4609] Previous case--control studies, conducted in diverse population to assess the relationship of CRC with *CTLA-4* polymorphisms, have generated conflicting findings. Hence, we undertook a study to determine whether *CTLA-4* variations could cause a predisposition toward CRC. In this study, we analyzed the tagging SNPs of *CTLA-4* (rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C, and rs231775 G\>A polymorphisms) and identified whether these SNPs confer susceptibility to CRC in an Eastern Chinese Han population.

Patients and methods
====================

Study population and patient selection
--------------------------------------

The study population consisted of 2,306 subjects (1,003 diagnosed as sporadic CRC and 1,303 controls) between October 2014 and August 2017. Among them, 757 CRC patients and 680 controls were enrolled from the Affiliated Union Hospital of Fujian Medical University (Fuzhou, China), and 246 CRC patients and 623 controls were enrolled from the Affiliated People's Hospital of Jiangsu University (Zhenjiang, China). CRC was confirmed via pathology. The age of CRC cases ranged from 21 to 90 years old (mean age at diagnosis was 61.10±12.17 years). The major exclusion criteria were autoimmune disorders, hereditary nonpolyposis CRC, and history of another malignancy. CRC cases who had received neo-adjuvant chemoradiotherapy were also excluded. The age of controls ranged from 21 to 87 years old (mean age at sampling was 61.40±9.61 years). In this study, the cancer-free controls included 1,303 healthy volunteers who participated in a routine examination in hospitals mentioned above. The primary information of the participants was collected by a pre-structured questionnaire. The definitions of "ever smokers" and "ever drinkers" are described in our previous study.[@b20-ott-11-4609] In addition, according to the criterion for overweight and obesity, a body mass index (BMI) of 24 was used as the cutoff point in Chinese adults.[@b21-ott-11-4609],[@b22-ott-11-4609] Each participant was informed about the present study and signed a standard informed consent form. The Ethical Committee of Fujian Medical University and Jiangsu University approved the protocols of the study (No KY-2013--11 and No 2012-00-18, respectively).

Data collection
---------------

All participants were personally questioned by two experienced doctors. The questionnaire included the primary information about demographics (eg, age, sex), smoking, drinking, height, and weight ([Table 1](#t1-ott-11-4609){ref-type="table"}). The clinical and pathological information of CRC cases was collected from their medical records.

Selection of tagging SNPs
-------------------------

The tagging SNPs across the entire region of *CTLA-4* gene (16.2 kbp spanning from 203862788--203878960 in chromosome 2 \[upstream and downstream of gene extending 5 kb, respectively\]) were selected from the Chinese Han in Beijing cohort via the HapMap Project (<http://hapmap.ncbi.nlm.nih.gov/index.html.en>) and analyzed with Haploview 4.2 software using a pairwise linkage disequilibrium (LD) *r*^2^ threshold of 0.8 between SNPs (with a minimum LD of *r*^2^\>0.8). SNPs with a Hardy--Weinberg equilibrium (HWE) *P*≥0.05, minor allele frequency (MAF) ≥0.05, and call rate ≥95% in the CHB cohort were included.[@b23-ott-11-4609] The detailed information of the selected four SNPs is summarized in [Table 2](#t2-ott-11-4609){ref-type="table"}.

DNA extraction and genotyping
-----------------------------

Ethylenediamine tetraacetic acid (EDTA)-anticoagulated intravenous blood was collected after an overnight fast. The genomic DNA was isolated using the Promega DNA Blood Mini Kit (Promega, Madison, WI, USA).

The genotyping of the *CTLA-4* rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C, and rs231775 G\>A polymorphisms were performed by a custom-by-design 48-Plex SNPscan Kit (Genesky Biotechnologies Inc., Shanghai, China) as described in previous studies.[@b24-ott-11-4609],[@b25-ott-11-4609] This 48-Plex SNPscan Kit was based on double ligation and multiplex fluorescence PCR.[@b26-ott-11-4609] For quality control, 92 (4%) samples were randomly selected and were tested again by the same genotyping method. The accordance ratio was 100%.

Statistical analysis
--------------------

Statistical analysis was performed using SAS version 9.4 software package for Windows (SAS Institute, Cary, NC, USA), and a *P*\<0.05 (two-tailed) was considered for level of significance. The continuous variables were expressed as mean±SD. We used the Student's *t*-test to check the differences for normally distributed continuous variables between CRC cases and controls. We used the chi-squared test to determine the differences in demographic variables, risk factors (smoking, BMI, and drinking), and the frequencies of genotype between CRC cases and controls. An internet-based calculator program (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) was harnessed to examine the deviation of HWE.[@b14-ott-11-4609] Multivariate logistic regression was used to analyze the associations between *CTLA-4* rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C, and rs231775 G\>A SNPs and risk of CRC. The relationships between *CTLA-4* rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C, and rs231775 G\>A polymorphisms genotypes and risk of CRC were assessed by crude/adjusted ORs and the corresponding 95% CIs when appropriate. The relationships were assessed in additive, homozygote, dominant, and recessive models. We used a Bonferroni correction to adjust for multiple testing.[@b27-ott-11-4609],[@b28-ott-11-4609]

Results
=======

Demographic characteristics
---------------------------

In our study, 1,003 CRC patients were included. Of them, 620 were males (61.81%) and 383 were females (38.19%). The mean age and SD were 61.10±12.17 years. The primary tumor site was the colon in 431 (42.97%) patients and the rectum in 572 (57.03%) patients. For the control group, we recruited 1,303 non-cancer controls, 801 males (61.47%) and 502 females (38.53%). Their age mean±SD was 61.40±9.61 years. All participants were Chinese Han population. The differences of age and sex between CRC and control groups were not statistically significant (*P*≥0.05) ([Table 1](#t1-ott-11-4609){ref-type="table"}). As summarized in [Table 1](#t1-ott-11-4609){ref-type="table"}, significant differences were found on alcohol consumption, smoking status, and BMI between the cases and the controls (*P*=0.002, \<0.001, and \<0.001, respectively). The primary information for CTLA-4 rs733618 T\>C, rs3087243 G\>A, rs16840252 C\>T, and rs231775 G\>A SNPs is shown in [Table 2](#t2-ott-11-4609){ref-type="table"}. For these SNPs, the successful ratio was more than 98.50%. In controls, MAF of CTLA-4 tagging SNPs was very close to the MAF data for Chinese ([Table 2](#t2-ott-11-4609){ref-type="table"}). [Table 2](#t2-ott-11-4609){ref-type="table"} shows the genotype frequencies of CTLA-4 tagging SNPs polymorphisms were all in HWE.

Association of CTLA-4 rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C, and rs231775 G\>A polymorphisms with CRC in overall analysis
----------------------------------------------------------------------------------------------------------------------------------

The frequencies of *CTLA-4* rs733618 TT, TC, and CC genotypes were 35.31%, 47.35%, and 17.35% in the CRC group and 35.23%, 47.15%, and 17.62% in the control group, respectively ([Table 3](#t3-ott-11-4609){ref-type="table"}). The frequencies of *CTLA-4* rs16840252 CC, CT, and TT genotypes were 75.71%, 22.76%, and 1.53% in the CRC group and 77.38%, 21.77%, and 0.85% in controls, respectively ([Table 3](#t3-ott-11-4609){ref-type="table"}). There was no statistically significant difference in genotype distribution of *CTLA-4* rs16840252 C\>T and rs733618 T\>C polymorphisms among CRC patients and controls. The frequencies of *CTLA-4* rs3087243 GG, GA, and AA genotypes were 65.00%, 30.20%, and 4.80% in the CRC group and 65.38%, 31.38%, and 3.23% in controls, respectively ([Table 3](#t3-ott-11-4609){ref-type="table"}). The *CTLA-4* rs3087243 AA genotype was associated with a borderline statistically increased risk of CRC, compared with *CTLA-4* rs3087243 GG/GA genotypes (crude OR=1.51, 95% CI=0.99--2.31, *P*=0.058). When adjusted for age, sex, BMI, smoking, and drinking, a borderline statistically increased risk of CRC was also found (crude OR=1.52, 95% CI=0.99--2.34, *P*=0.058; [Table 4](#t4-ott-11-4609){ref-type="table"}).

The frequencies of *CTLA-4* rs231775 GG, GA, and AA genotypes were 42.59%, 45.25%, and 12.16% in the CRC group and 47.77%, 43.31%, and 8.85% in the control group, respectively ([Table 3](#t3-ott-11-4609){ref-type="table"}). When compared with the *CTLA-4* rs231775 GG genotype, *CTLA-4* rs231775 AA and GA/AA genotypes significantly increased the risk of CRC (homozygote model: crude OR=1.47, 95% CI=1.10--1.95, *P*=0.008; and dominant model: crude OR=1.23, 95% CI=1.05--1.46, *P*=0.014). When compared with *CTLA-4* rs231775 GG/GA genotypes, the *CTLA-4* rs231775 AA genotype also increased the risk of CRC (crude OR=1.43, 95% CI=1.09--1.87, *P*=0.011). When adjusting for age, sex, BMI, smoking, and drinking, the results were not essentially changed (homozygote model: adjusted OR=1.40, 95% CI=1.05--1.87, *P*=0.022; dominant model: adjusted OR=1.19, 95% CI=1.00--1.41, *P*=0.047; and recessive model: adjusted OR=1.38, 95% CI= 1.05--1.82, *P*=0.021; [Table 4](#t4-ott-11-4609){ref-type="table"}).

Association of CTLA-4 rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C, and rs231775 G\>A polymorphisms with CRC in a stratification group by primary site of tumor
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether the effect of *CTLA-4* tagging SNPs was modified by the primary site of tumor, we performed a stratified analysis. For *CTLA-4* rs16840252 C\>T, stratified analysis revealed this polymorphism was associated with an increased risk of colon cancer (homozygote model: adjusted OR=2.51, 95% CI=1.04--6.03, *P*=0.040 and recessive model: adjusted OR=2.54, 95% CI=1.06--6.09, *P*=0.037; [Table 4](#t4-ott-11-4609){ref-type="table"}). For the *CTLA-4* rs231775 G\>A polymorphism, we found that *CTLA-4* rs231775 AA genotypes might be associated with an increased risk of colon cancer (homozygote model: adjusted OR=1.61, 95% CI=1.12--2.30, *P*=0.010 and recessive model: adjusted OR=1.59, 95% CI=1.13--2.23, *P*=0.009; [Table 4](#t4-ott-11-4609){ref-type="table"}). The results of other genetic comparisons are summarized in [Table 4](#t4-ott-11-4609){ref-type="table"}.

Association of CTLA-4 rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C, and rs231775 G\>A polymorphisms with CRC in a stratification group by geographical area
-------------------------------------------------------------------------------------------------------------------------------------------------------------

In this study, CRC patients and controls were enrolled from two different geographical areas (Fuzhou and Zhenjiang, China). We performed a stratified analysis according to geographical area. Compared with *CTLA-4* rs231775 GG, we found *CTLA-4* rs231775 GA/AA genotypes might be associated with an increased risk of CRC in the Zhenjiang cohort (adjusted OR=1.38, 95% CI=1.01--1.88, *P*=0.041; [Table 5](#t5-ott-11-4609){ref-type="table"}). In addition, the stratified analysis revealed the *CTLA-4* rs231775 G\>A polymorphism also had a tendency of increased risk to CRC in the Fuzhou cohort (recessive model: adjusted OR=1.40, 95% CI=0.99--1.98, *P*=0.061; [Table 5](#t5-ott-11-4609){ref-type="table"}).

SNP haplotypes
--------------

Using an expectation--maximization algorithm (SHESIS program; Bio-X Inc., Shanghai, China, <http://analysis.bio-x.cn/myAnalysis.php>),[@b29-ott-11-4609] we constructed seven hap-lotypes ([Table 6](#t6-ott-11-4609){ref-type="table"}). Haplotype comparison analysis suggested that CTLA4 G~rs3087243~C~rs16840252~C~rs733618~A~rs231775~, G~rs3087243~C~rs16840252~T~rs733618~A~rs231775~, and other haplotypes significantly increased the risk of CRC (*P*\<0.001, \<0.001, and 0.002, respectively, [Table 6](#t6-ott-11-4609){ref-type="table"}).

Discussion
==========

The individual's susceptibility to CRC may be diverse, even with the same environmental exposure. Host genetic predisposition may lead to these differences. In recent years, several case--control studies have been performed to test the hypothesis that some functional variants in *CTLA-4* and other immune checkpoint molecules such as *HLA-G* may influence the risk and the treatment of CRC.[@b30-ott-11-4609]--[@b36-ott-11-4609] Garziera et al[@b36-ott-11-4609] reported that HLA-G 3′UTR polymorphisms might significantly affect the development of CRC. However, the association between CRC susceptibility and *CTLA-4* polymorphisms remain conflicting. In addition, a comprehensive assessment was lacking. The aim of the present study was to identify the association between *CTLA-4* tagging polymorphisms (rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C, and rs231775 G\>A) and susceptibility of CRC in a case--control study. Genotyping of 1,003 CRC cases and 1,303 cancer-free controls was carried out in an Eastern Chinese Han population. Our findings demonstrated that *CTLA-4* rs231775 G\>A polymorphism might be associated with the risk of CRC. In a stratified analysis by primary site of tumor, the association was also found in colon cancer. When a subgroup analysis was performed by cohort, we also found *CTLA-4* rs231775 GA/AA genotypes might be associated with an increased risk of CRC in the Zhenjiang cohort. Additionally, we found the *CTLA-4* rs16840252 C\>T polymorphism was associated with a risk of colon cancer. Haplotype comparison analysis showed that *CTLA4* G~rs3087243~C~rs16840252~C~rs733618~A~rs231775~, G~rs3087243~C~rs16840252~T~rs733618~A~rs231775~, and other haplotypes increased the risk of CRC. Based on these primary findings, we found *CTLA-4* tagging polymorphisms and haplotypes might influence the susceptibility to developing CRC.

Several case--control studies focused on the association between *CTLA-4* rs16840252 C\>T polymorphism and risk of cancer.[@b37-ott-11-4609],[@b38-ott-11-4609] The observed results indicated that the *CTLA-4* rs16840252 C\>T polymorphism might not confer a risk to cancer. However, *CTLA-4* rs16840252 C\>T located in the promoter region of the *CTLA4* gene. HapMap data suggest that *CTLA-4* rs16840252 C\>T and rs4553808 C\>T (−1,661 C\>T) are in complete LD.[@b37-ott-11-4609] Interestingly, Idris et al[@b39-ott-11-4609] also reported that strong LD was found between *CTLA-4* rs16840252 C\>T and rs5742909 C\>T (−318 C\>T) across all LD structures in an Asian population. In the presence of these functional SNPs on the same LD block, it could be that the predisposing allele of *CTLA-4* rs4553808 C\>T or rs5742909 C\>T polymorphism is in LD with the protective allele of rs16840252 C\>T. Ligers et al[@b40-ott-11-4609] found that individuals carrying thymine at position −318 of the CTLA4 promoter (*CTLA-4* rs5742909 C\>T) showed significantly increased expression, both of CTLA-4 mRNA in non-stimulated cells and of cell-surface CTLA-4 after cellular stimulation. Recently, several meta-analyses indicated that *CTLA-4* rs4553808 T\>C and rs5742909 C\>T polymorphisms were associated with the risk of cancer, especially in Asians.[@b33-ott-11-4609],[@b41-ott-11-4609],[@b42-ott-11-4609] Since *CTLA-4* rs16840252 C\>T, rs5742909 C\>T, and rs4553808 T\>C are in strong LD, the function of *CTLA-4* rs16840252 C\>T could be influenced by *CTLA-4* rs4553808 C\>T or rs5742909 C\>T. To the best of our knowledge, this case--control study was the first investigation to assess the association between *CTLA-4* rs16840252 C\>T genotype and CRC risk. Our findings indicated the *CTLA-4* rs16840252 C\>T polymorphism represented a risk factor for colon cancer. Our findings are supported by those pool-analyses mentioned above.

The *CTLA-4* rs231775 G\>A polymorphism was the most frequently explored and was established as a functional SNP of the *CTLA-4* gene.[@b43-ott-11-4609],[@b44-ott-11-4609] The *CTLA-4* rs231775 G\>A (c.49 G\>A) SNP causes p.17Ala \>17 Thr change in the leading sequence of CTLA-4 receptor.[@b40-ott-11-4609],[@b44-ott-11-4609] Previous studies have demonstrated that the *CTLA-4* rs231775 G allele has a lower mRNA efficiency and downregulates CTLA-4 protein more than the *CTLA-4* rs231775 A allele.[@b45-ott-11-4609] Therefore, individuals who carry the *CTLA-4* rs231775 AA genotype have lower T-cell proliferation and immune response than those with the *CTLA-4* rs231775 GG genotype.[@b44-ott-11-4609] Sun et al[@b43-ott-11-4609] also found that the p.17Ala \>17 Thr substitution in CTLA-4 amino acid residue caused by the c.49 G\>A SNP significantly increased the interaction of the CTLA-4 receptor with its ligand B7.1, and recombinant CTLA-4-17Thr had a higher inhibitory effect to T-cell proliferation and immune response compared with CTLA-4-17Ala. These primary studies suggested that p.17Ala.17 Thr change in CTLA-4 may lead to a significant effect of T-cell proliferation and activation. A previous study demonstrated that donor *CTLA-4* rs231775 genotype modulates the immune response to minor histocompatibility antigen mismatches.[@b46-ott-11-4609] The *CTLA-4* rs231775 genotype was also considered as a genetic determinant in autoimmune Addison's disease.[@b47-ott-11-4609] Recently, a number of case--control studies focused on the relationship between *CTLA-4* rs231775 G\>A SNP and the risk of cancer, and results of subsequent meta-analyses evidenced that the *CTLA-4* rs231775 G\>A polymorphism was a risk factor for multiple cancer, especially in Asian populations.[@b32-ott-11-4609]--[@b35-ott-11-4609] Three pooled-analysis studies also suggested that this polymorphism was associated with the development of CRC.[@b15-ott-11-4609]--[@b17-ott-11-4609] Although these findings tried to suggest an association between *CTLA-4* rs231775 G\>A polymorphism and CRC, the number of included studies and participants were limited. Thus, we conducted this case--control study with larger sample sizes to explore whether the *CTLA-4* rs231775 G\>A polymorphism was a risk factor for CRC. As demonstrated in [Table 4](#t4-ott-11-4609){ref-type="table"}, we found that this polymorphism was associated with an increased risk of CRC. We also studied the association of *CTLA-4* rs231775 G\>A polymorphism with CRC in different subgroups. Similar findings were also found when the Bonferroni correction was applied. The association was also significant in the colon cancer subgroup (AA vs GG: OR=1.61; 95% CI=1.12--2.30; *P*=0.010 and AA vs GG/GA: OR=1.59; 95% CI=1.13--2.23; *P*=0.009; [Table 4](#t4-ott-11-4609){ref-type="table"}). Results of the present study were in accordance with results of those meta-analyses and functional studies mentioned above.

*CTLA-4* rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C, and rs231775 G\>A variants may not be inherited randomly. As summarized in [Table 6](#t6-ott-11-4609){ref-type="table"}, we found the frequency of G~rs3087243~C~rs16840252~C~rs733618~A~rs231775~, G~rs3087243~C~rs16840252~ T~rs733618~A~rs231775~, and other haplotypes was significantly increased in CRC patients. We first reported the association of these *CTLA-4* haplotypes with CRC susceptibility. A previous study suggested that the *CTLA4* G~rs3087243~C~rs16840252~ C~rs733618~A~rs231775~ haplotype significantly increased the risk of gastric cardia adenocarcinoma,[@b14-ott-11-4609] which was similar to our findings. However, these *CTLA4* haplotypes only influenced a very minor fraction (less than 2%) of the CRC patients.

Of note, we focused on the relationship of CTLA-4 tagging SNPs with CRC risk in an Eastern Chinese Han population. In addition, the sample size of our study was larger than before. Finally, the MAF in our controls was very similar to the data for Chinese in the database ([Table 2](#t2-ott-11-4609){ref-type="table"}).

Although there were some merits in our study, some limitations should also be addressed. First, this study was designed as a hospital-based investigation; the CRC patients and controls were recruited from hospitals in Eastern China and might not well represent the whole Eastern Chinese Han population. Second, the recruited CRC cases were moderate in stratified analyses. In the future, these findings should be verified in well-designed studies with a larger sample size. Third, because of the limited sample size of CRC patients and absence of a validation cohort, the power of the present study may be insufficient, especially in stratified analyses. Fourth, for insufficient samples, a replicated study was not conducted. Fifth, due to lack of other information, we did not carry out a further evaluation of potential interaction, such as dietary habit, family history, hormone level, intake of vitamins, other environmental factors, and lifestyles. In considering the complexity of CRC etiology, the gene--environment interaction should not be ignored. Finally, in our case--control study, we investigated four tagging SNPs in the *CTLA-4* gene and did not focus on other functional SNPs. In the future, a fine-mapping study is needed to further identify any potential association.

Conclusion
==========

In summary, the findings of our case--control study evidence that *CTLA-4* rs16840252 C\>T and rs231775 G\>A SNPs are correlated with genetic susceptibility for development of CRC in an Eastern Chinese Han population. Additionally, this study first highlights that *CTLA-4* rs16840252 C\>T polymorphism increases the susceptibility of CRC. Furthermore, findings are consistent with the biological functions of tagging SNPs in the *CTLA-4* gene and validate the hypothesis that *CTLA-4* tagging polymorphisms, which alter CTLA-4 mRNA and/or protein expression, may influence normal immune functions and lead to an increased risk of CRC.
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###### 

Distribution of selected demographic variables and risk factors in CRC cases and controls

  Variable                     Cases (n=1,003)   Controls (n=1,303)   *P*-value[a](#tfn2-ott-11-4609){ref-type="table-fn"}           
  ---------------------------- ----------------- -------------------- ------------------------------------------------------ ------- -----------
  Age (years), M (±SD)         61.10 (±12.17)                         61.40 (±9.61)                                                  0.496
  Age (years)                                                                                                                        0.605
   \<61                        451               44.97                600                                                    46.05   
   ≥61                         552               55.03                703                                                    53.95   
  Sex                                                                                                                                0.867
   Male                        620               61.81                801                                                    61.47   
   Female                      383               38.19                502                                                    38.53   
  Smoking status                                                                                                                     *0.002*
   Never                       744               74.18                1,038                                                  79.66   
   Ever                        259               25.82                265                                                    20.34   
  Alcohol use                                                                                                                        \<*0.001*
   Never                       829               82.65                1,167                                                  89.56   
   Ever                        174               17.35                136                                                    10.44   
  BMI (kg/m^2^)                                                                                                                      \<*0.001*
   \<24                        670               66.80                688                                                    52.80   
   ≥24                         333               33.20                615                                                    47.20   
  Primary site of tumor                                                                                                              
   Colon cancer                431               42.97                                                                               
   Rectum cancer               572               57.03                                                                               
  Degree of differentiation                                                                                                          
   Poorly differentiated       124               12.36                                                                               
   Moderately differentiated   832               82.95                                                                               
   Well differentiated         47                4.69                                                                                
  Lymph node status                                                                                                                  
   Positive                    518               51.65                                                                               
   Negative                    485               48.35                                                                               
  AJCC TMN stage                                                                                                                     
   0--I                        167               16.65                                                                               
   II                          290               28.91                                                                               
   III                         420               41.87                                                                               
   IV                          126               12.56                                                                               

**Notes:** Italic values are statistically significant (*P*\<0.05).

Two-sided chi-squared test and Student's *t*-test.

**Abbreviations:** CRC, colorectal cancer; SD, standard deviation; BMI, body mass index; AJCC, American Joint Committee on Cancer.

###### 

Primary information for *CTLA-4* polymorphisms

  Genotyped SNPs                           *CTLA-4* rs3087243 G\>A   *CTLA-4* rs231775 G\>A   *CTLA-4* rs16840252 C\>T   *CTLA-4* rs733618 T\>C
  ---------------------------------------- ------------------------- ------------------------ -------------------------- ------------------------
  Chromosome                               2                         2                        2                          2
  Function                                 nearGene-3                Missense                 nearGene-5                 nearGene-5
  Location                                 Intron 3+6,230            Exon 1+49                Promoter 1147              Promoter 1722
  Chr Pos (Genome Build 38)                203874196                 203867991                203866796                  203866221
  MAF for Chinese in database              0.183                     0.314                    0.122                      0.390
  MAF in our controls (n=1,303)            0.189                     0.305                    0.117                      0.412
  *P*-value for HWE test in our controls   0.411                     0.430                    0.065                      0.335
  Genotyping method                        SNPscan                   SNPscan                  SNPscan                    SNPscan
  \% Genotyping value                      98.87%                    98.79%                   98.87%                     98.87%

**Abbreviations:** SNP, single-nucleotide polymorphism; MAF, minor allele frequency; HWE, Hardy--Weinberg equilibrium.

###### 

The frequencies of *CTLA-4* rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C, and rs231775 G\>A polymorphisms in CRC patients and controls

  Genotype          CRC cases (n=1,003)   Colon cancer (n=431)   Rectum cancer (n=572)   Controls (n=1,303)                         
  ----------------- --------------------- ---------------------- ----------------------- -------------------- ----- ------- ------- -------
  rs3087243 G\>A                                                                                                                    
   GG               637                   65.00                  271                     64.07                366   65.71   850     65.38
   GA               296                   30.20                  132                     31.21                164   29.44   408     31.38
   AA               47                    4.80                   20                      4.73                 27    4.85    42      3.23
   A allele         390                   19.90                  172                     20.33                218   19.57   492     18.92
  rs16840252 C\>T                                                                                                                   
   CC               742                   75.71                  319                     75.41                423   75.94   1,006   77.38
   CT               223                   22.76                  94                      22.22                129   23.16   283     21.77
   TT               15                    1.53                   10                      2.36                 5     0.90    11      0.85
   T allele         253                   12.91                  114                     13.48                139   12.48   305     11.73
  rs733618 T\>C                                                                                                                     
   TT               346                   35.31                  140                     33.10                206   36.98   458     35.23
   TC               464                   47.35                  216                     51.06                248   44.52   613     47.15
   CC               170                   17.35                  67                      15.84                103   18.49   229     17.62
   C allele         804                   41.02                  350                     41.37                454   40.75   1,071   41.19
  rs231775 G\>A                                                                                                                     
   GG               417                   42.59                  178                     42.18                239   42.91   621     47.77
   GA               443                   45.25                  187                     44.31                256   45.96   563     43.31
   AA               119                   12.16                  57                      13.51                62    11.13   115     8.85
   A allele         681                   34.78                  301                     35.66                380   34.11   793     30.50

**Abbreviation:** CRC, colorectal cancer.

###### 

Overall and stratified analyses of *CTLA-4* rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C, and rs231775 G\>A polymorphisms with CRC by region

  Genotype            CRC cases (n=1,003) vs controls (1,303)   Colon cancer (n =431) vs controls (1,303)   Rectum cancer (n =572) vs controls (1,303)                                                                                                                   
  ------------------- ----------------------------------------- ------------------------------------------- -------------------------------------------- ------- ------------------- ------- ------------------- ------- ------------------- ------- ------------------- -------
  rs3087243 G\>A                                                                                                                                                                                                                                                         
   Additive model     0.94 (0.78--1.12)                         0.485                                       0.89 (0.74--1.07)                            0.223   0.99 (0.78--1.26)   0.929   0.95 (0.74--1.20)   0.654   0.90 (0.72--1.12)   0.343   0.86 (0.69--1.07)   0.182
   Homozygote model   1.45 (0.94--2.22)                         0.091                                       1.43 (0.93--2.21)                            0.106   1.46 (0.84--2.52)   0.180   1.48 (0.85--2.59)   0.165   1.44 (0.87--2.37)   0.152   1.38 (0.83--2.28)   0.216
   Dominant model     1.02 (0.86--1.21)                         0.849                                       0.97 (0.81--1.16)                            0.754   1.06 (0.84--1.33)   0.621   1.02 (0.81--1.29)   0.865   0.99 (0.80--1.22)   0.893   0.94 (0.76--1.17)   0.588
   Recessive model    1.51 (0.99--2.31)                         0.058                                       1.52 (0.99--2.34)                            0.058   1.49 (0.86--2.56)   0.153   1.54 (0.89--2.67)   0.125   1.53 (0.93--2.50)   0.094   1.48 (0.90--2.45)   0.125
  rs16840252 C\>T                                                                                                                                                                                                                                                        
   Additive model     1.04 (0.85--1.27)                         0.704                                       1.02 (0.84--1.25)                            0.816   1.03 (0.79--1.34)   0.855   1.02 (0.78--1.33)   0.902   1.05 (0.83--1.33)   0.684   1.03 (0.81--1.31)   0.821
   Homozygote model   1.80 (0.82--3.94)                         0.142                                       1.72 (0.78--3.81)                            0.182   2.80 (1.18--6.66)   0.020   2.51 (1.04--6.03)   0.040   1.05 (0.36--3.03)   0.932   0.96 (0.33--2.84)   0.943
   Dominant model     1.10 (0.90--1.34)                         0.349                                       1.08 (0.89--1.32)                            0.441   1.12 (0.86--1.44)   0.404   1.10 (0.85--1.43)   0.468   1.08 (0.86--1.37)   0.499   1.06 (0.84--1.35)   0.632
   Recessive model    1.82 (0.83--3.98)                         0.133                                       1.72 (0.79--3.86)                            0.170   2.84 (1.20--6.73)   0.018   2.54 (1.06--6.09)   0.037   1.06 (0.37--3.07)   0.911   0.98 (0.33--2.89)   0.965
  rs733618 T\>C                                                                                                                                                                                                                                                          
   Additive model     0.95 (0.79--1.14)                         0.548                                       0.97 (0.81--1.17)                            0.772   1.10 (0.86--1.40)   0.450   1.12 (0.88--1.43)   0.374   0.84 (0.68--1.05)   0.127   0.88 (0.71--1.10)   0.256
   Homozygote model   0.93 (0.73--1.18)                         0.540                                       0.97 (0.76--1.24)                            0.797   0.91 (0.66--1.27)   0.581   0.95 (0.68--1.33)   0.771   0.94 (0.71--1.24)   0.658   0.99 (0.74--1.32)   0.920
   Dominant model     1.00 (0.84--1.19)                         0.970                                       1.03 (0.87--1.23)                            0.729   1.10 (0.87--1.39)   0.423   1.13 (0.89--1.43)   0.307   0.93 (0.75--1.14)   0.470   0.97 (0.79--1.20)   0.771
   Recessive model    0.98 (0.79--1.22)                         0.868                                       1.01 (0.81--1.26)                            0.938   0.88 (0.65--1.19)   0.401   0.91 (0.67--1.23)   0.543   1.06 (0.82--1.37)   0.652   1.09 (0.84--1.42)   0.526
  rs231775 G\>A                                                                                                                                                                                                                                                          
   Additive model     1.12 (0.94--1.33)                         0.220                                       1.08 (0.90--1.28)                            0.422   1.11 (0.88--1.40)   0.379   1.07 (0.85--1.36)   0.553   1.12 (0.91--1.38)   0.289   1.08 (0.87--1.33)   0.481
   Homozygote model   1.47 (1.10--1.95)                         0.008                                       1.40 (1.05--1.87)                            0.022   1.66 (1.16--2.37)   0.006   1.61 (1.12--2.30)   0.010   1.33 (0.94--1.87)   0.105   1.22 (0.86--1.73)   0.256
   Dominant model     1.23 (1.05--1.46)                         0.014                                       1.19 (1.00--1.41)                            0.047   1.26 (1.01--1.57)   0.044   1.21 (0.97--1.52)   0.091   1.22 (1.00--1.49)   0.053   1.17 (0.95--1.43)   0.138
   Recessive model    1.43 (1.09--1.87)                         0.011                                       1.38 (1.05--1.82)                            0.021   1.61 (1.15--2.26)   0.006   1.59 (1.13--2.23)   0.009   1.29 (0.93--1.79)   0.126   1.21 (0.87--1.69)   0.260

**Note:**

Adjusted for age, sex, BMI, smoking status, and alcohol use in a logistic regression model.

**Abbreviations:** CRC, colorectal cancer; BMI, body mass index; OR, odds ratio; CI, confidence interval.

###### 

Logistic regression analyses of associations between *CTLA-4* polymorphisms and risk of CRC in two cohorts

  Genotype          Zhenjiang cohort   Fuzhou cohort                                                                                             
  ----------------- ------------------ --------------- ----- ------- ------------------- ------- ----- ------- ----- ------- ------------------- -------
  rs231775 G\>A                                                                                                                                  
   GG               100                42.37           319   51.37   1.00                        317   42.66   302   44.54   1.00                
   GA               110                46.61           251   40.42   1.21 (0.88--1.66)   0.241   333   44.82   312   46.02   0.93 (0.74--1.17)   0.526
   AA               26                 11.02           51    8.21    1.50 (0.88--2.55)   0.135   93    12.52   64    9.44    1.32 (0.92--1.90)   0.138
   GA + AA          136                57.63           302   48.63   1.38 (1.01--1.88)   0.041   426   57.34   376   55.46   1.03 (0.83--1.29)   0.765
   GG + GA          210                88.98           570   91.79   1.00                        650   87.48   614   90.56   1.00                
   AA               26                 11.02           51    8.21    1.45 (0.87--2.41)   0.155   93    12.52   64    9.44    1.40 (0.99--1.98)   0.061
   A allele         162                34.32           353   28.42                               519   34.93   440   32.45                       
  rs16840252 C\>T                                                                                                                                
   CC               175                74.15           478   76.97   1.00                        567   76.21   528   77.76   1.00                
   CT               59                 25.00           137   22.06   1.08 (0.76--1.55)   0.656   164   22.04   146   21.50   1.05 (0.81--1.36)   0.721
   TT               2                  0.85            6     0.97    0.81 (0.16--4.12)   0.800   13    1.75    5     0.74    2.13 (0.73--6.21)   0.164
   CT + TT          61                 25.85           143   23.03   1.13 (0.80--1.61)   0.484   177   23.79   151   22.24   1.12 (0.86--1.44)   0.408
   CC + CT          234                99.15           615   99.03   1.00                        731   98.25   674   99.26   1.00                
   TT               2                  0.85            6     0.97    0.83 (0.16--4.22)   0.825   13    1.75    5     0.74    2.14 (0.74--6.23)   0.162
   T allele         63                 13.35           149   12.00                               190   12.77   156   11.49                       
  rs3087243 G\>A                                                                                                                                 
   GG               175                74.15           433   69.73   1.00                        462   62.10   417   61.41   1.00                
   GA               54                 22.88           170   27.38   0.75 (0.52--1.07)   0.108   242   32.53   238   35.05   0.83 (0.66--1.04)   0.108
   AA               7                  2.97            18    2.90    0.88 (0.36--2.18)   0.787   40    5.38    24    3.53    1.39 (0.81--2.39)   0.234
   GA + AA          61                 25.85           188   30.27   0.80 (0.57--1.13)   0.208   282   37.90   262   38.59   0.90 (0.72--1.13)   0.368
   GG + GA          229                97.03           603   97.10   1.00                        704   94.62   655   96.47   1.00                
   AA               7                  2.97            18    2.90    0.99 (0.40--2.42)   0.974   40    5.38    24    3.53    1.51 (0.89--2.59)   0.130
   A allele         68                 14.41           206   16.59                               322   23.71   286   21.06                       
  rs733618 T\>C                                                                                                                                  
   TT               70                 29.66           224   36.07   1.00                        276   37.10   234   34.46   1.00                
   TC               123                52.12           296   47.67   1.17 (0.84--1.64)   0.349   341   45.83   317   46.69   0.89 (0.70--1.13)   0.341
   CC               43                 18.22           101   16.26   1.27 (0.81--1.99)   0.293   127   17.07   128   18.85   0.83 (0.61--1.14)   0.247
   TC + CC          166                70.34           397   63.93   1.36 (0.97--1.88)   0.071   468   62.90   445   65.54   0.92 (0.73--1.15)   0.460
   TT + TC          193                81.78           520   83.74   1.00                        617   82.93   551   81.15   1.00                
   CC               43                 18.22           101   16.26   1.21 (0.81--1.81)   0.348   127   17.07   128   18.85   0.91 (0.68--1.20)   0.497
   C allele         209                44.28           498   40.10                               595   39.99   573   42.19                       

**Note:**

Adjusted for age, sex, BMI, smoking status, and alcohol use.

**Abbreviations:** CRC, colorectal cancer; OR, odds ratio; CI, confidence interval; BMI, body mass index.

###### 

*CTLA-4* haplotype frequencies (%) in cases and controls and risk of CRC

  Haplotypes                                                   CRC cases (n=2,006)   Controls (n=2,606)   Crude OR (95% CI)   *P*-value                         
  ------------------------------------------------------------ --------------------- -------------------- ------------------- ----------- --------------------- ---------
  *CTLA4* G~rs3087243~ C~rs16840252~ C~rs733618~ G~rs231775~   765                   39.11                1,069               41.15       1.00                  
  *CTLA4* G~rs3087243~ C~rs16840252~ T~rs733618~ G~rs231775~   490                   25.05                726                 27.94       0.94 (0.81--1.09)     0.437
  *CTLA4* A~rs3087243~ C~rs16840252~ T~rs733618~ A~rs231775~   382                   19.53                492                 18.94       1.08 (0.92--1.28)     0.326
  *CTLA4* G~rs3087243~ T~rs16840252~ T~rs733618~ A~rs231775~   237                   12.12                294                 11.32       1.13 (0.93--1.37)     0.230
  *CTLA4* G~rs3087243~ C~rs16840252~ C~rs733618~ A~rs231775~   34                    1.74                 2                   0.08        23.76 (5.69--99.21)   \<0.001
  *CTLA4* G~rs3087243~ C~rs16840252~ T~rs733618~ A~rs231775~   26                    1.33                 5                   0.19        7.27 (2.78--19.01)    \<0.001
  Others                                                       22                    1.12                 10                  0.38        3.07 (1.45--6.53)     0.002

**Abbreviations:** CRC, colorectal cancer; OR, odds ratio; CI, confidence interval.
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